Emerging evidence of the health benefits of S-equol, an estrogen receptor β agonist
RL Jackson, JS Greiwe, RJ Schwen - Nutrition reviews, 2011 - academic.oup.com
RL Jackson, JS Greiwe, RJ Schwen
Nutrition reviews, 2011•academic.oup.comMany clinical studies have been carried out to determine the health benefits of soy protein
and the isoflavones contained in soy. S-equol is not present in soybeans but is produced
naturally in the gut of certain individuals, particularly Asians, by the bacterial
biotransformation of daidzein, a soy isoflavone. In those intervention studies in which
plasma S-equol levels were determined, a concentration of> 5–10 ng/mL has been
associated with a positive outcome for vasomotor symptoms, osteoporosis (as measured by …
and the isoflavones contained in soy. S-equol is not present in soybeans but is produced
naturally in the gut of certain individuals, particularly Asians, by the bacterial
biotransformation of daidzein, a soy isoflavone. In those intervention studies in which
plasma S-equol levels were determined, a concentration of> 5–10 ng/mL has been
associated with a positive outcome for vasomotor symptoms, osteoporosis (as measured by …
Abstract
Many clinical studies have been carried out to determine the health benefits of soy protein and the isoflavones contained in soy. S-equol is not present in soybeans but is produced naturally in the gut of certain individuals, particularly Asians, by the bacterial biotransformation of daidzein, a soy isoflavone. In those intervention studies in which plasma S-equol levels were determined, a concentration of >5–10 ng/mL has been associated with a positive outcome for vasomotor symptoms, osteoporosis (as measured by an increase in bone mineral density), prostate cancer, and the cardiovascular risk biomarkers low-density lipoprotein cholesterol and C-reactive protein. These studies suggest that S-equol may provide therapeutic benefits for a number of medical needs.
Oxford University Press